The progression of research concepts, experimental hypotheses and medical device development, typically, has its genesis from a clinical problem. Clinical problems often place limits on the optimal application of any treatment or procedure. For instance, if safety and efficacy was not a problem, wouldn't extracorporeal circulation be conducted without systemic anticoagulation? It is a fact that anticoagulation is required, but there has been much research over many decades to alleviate the pitfalls of no anticoagulation. Heparin is still universally used, but there is ongoing research to develop and use other anticoagulants, such as direct thrombin inhibitors or surface-bound modifications, to make the circuit inert to flowing blood. Would it not be safer if the expected risks or side-effects of the devices we use routinely were no longer a risk at all? What if a new generation of techniques or implantable artificial organs offset the enormous cost of current treatment modalities? Enter the research grant or contract, complete with the experimental laboratory, investigators and technicians to address the never-ending list of questions and follow-up on problems that present once one question is answered.
I was reminded of the following statement after a series of frustrating experimental results. "In the hospital we care for our patients with techniques and devices that rarely fail. In the lab we want devices and techniques to fail so it does not happen to a patient. Research will save thousands of lives. Ten years from now grateful families will be taking home healthy family members because of these devices and the work you do. The families won't know why it worked without complications, but you will. " (Personal communication, Dr. Robert H. Bartlett, 2016) It follows that medical research often progresses slowly. The evolution of temporary mechanical circulatory support leading to clinical use of the heart-lung machine was described more than a century ago and was developed over many decades by notable scientists in the 20 th century before Dr. John Gibbon's successful clinical use of a heart-lung machine in 1953. Prior to clinical implementation, Gibbon published his research findings in 13 other reports, with the first appearing in 1937. The time from concept to clinical implementation took decades.
Gas exchange materials also evolved slowly over time, beginning first with blood film or disc-based devices. The advent of the direct blood contact or bubble oxygenators gave way to early versions of membrane lungs that used Teflon, polyethylene, polypropylene and silicone rubber flat sheets. With the advent of stretched microporous polypropylene in a hollow-fiber configuration, second generation membrane lungs were characterized by better performance, with a smaller surface area allowing for longer use and expanded applications. The advent of the polymethylpentene fiber available today has allowed extracorporeal lung technology to be extended from days to weeks to months, all with minimal side-effects. This too took decades of ongoing research, development, and testing.
The past ten years has seen a proliferation of extended extracorporeal life support (or as it was first referred to as ECMO). It was first described in the 1960s and was developed in several laboratories. The first success was reported in 1972. 1 This led to the first multi-center, randomized control trial to compare the use of ECMO to conventional mechanical ventilation, but that trial was fraught with many mechanical and physiologic challenges and the results showed that ECMO provided no benefit in this patient subset because all the patients succumbed to their lung disease. 2 However, in the past two decades, adult ECMO has been revisited, primarily related to changes in ventilator management that advocates smaller tidal volumes, which are more lung protective. Many publications have supported a wider use of ECMO, but two are significant: the CESAR randomized control trial in adults 3 and the use of ECMO in the treatment of the H1N1 virus. 4 As the technology and understanding of the pathophysiologic effects of extracorporeal circulation have been better appreciated, it has widened the boundaries for implementation of this form of extracorporeal life support. However, accelerated progress is often not as fast as one might wish.
In 1982, Dr. Pierre Galletti chaired a panel discussion on the research and development of new concepts and devices. Many questions were raised that still remain It Just Takes Time 699068P RF0010.1177/0267659117699068PerfusionEditorial editorial2017 Editorial today, pertaining to the cost and regulatory aspects of any new device that might be commercialized. The panel debated the pathways in which a concept would enter the complex and expensive process of industrial development; the role of government regulation, decisions used by private industry in deciding whether or not to transform a prototype to the market; the role of academia; as well as laboratory and clinical evaluations. The panel further debated how the public and private sectors would interface in the areas of patent application, licensing arrangements, and developmental costs for useful devices with broad or limited market penetration. Ultimately, due to the public's demand for new and more complex devices, contrasted by regulation, would it be possible to turn device regulation in a positive manner and reflect the views and needs of public and patients? It all becomes a challenge because of the complexities of government, academia and industry. 5 Any new therapy, device, or technique has economic and professional ramifications. Galletti later would state that, "the level of risk that was justified when the field dealt only with desperate conditions is no longer acceptable for elective procedures and our attitudes must change accordingly. " He then went on to write, "It still takes 20 years to establish a 20-year clinical effectiveness. " 6 At times, we are presented with unique challenges that require some form of improvisation of existing or new technology in an attempt to accomplish an urgent clinical need while waiting for the next innovation. A journal can play a small part, for the description of a case study, device concept, or even a series of patient results may contribute the data or experience required for a technique or device to gain more acceptance. It just takes time.
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